What does “Approved Drug Products with Therapeutic Equivalence Evaluations (38th edition, 2018)” refer to?
That title refers to the U.S. Food and Drug Administration (FDA) publication Approved Drug Products with Therapeutic Equivalence Evaluations (often called the “Orange Book”). The 38th edition (2018) lists approved drug products and assigns therapeutic equivalence evaluations for generic drugs compared with their reference listed drugs. These evaluations are used to support substitution and pharmacy generic dispensing decisions under FDA’s therapeutic equivalence framework.
Where can I find the 38th edition (2018) Orange Book, and what should I look for?
To use it, search within the Orange Book for:
- Active ingredient
- Dosage form/route (for example, tablet, capsule, injectable)
- Strength
- Reference listed drug and the therapeutic equivalence rating (commonly used to indicate whether generics can be considered therapeutically equivalent)
In practice, people consult the Orange Book to answer questions like whether a generic product is FDA-approved and whether it is considered therapeutically equivalent to a listed brand-name drug.
Is “HHS file c users vhawla ... microsoftedgedownload” part of the Orange Book?
The text you pasted (“file c users vhawla 2 appdata local temp 4 microsoftedgedownload”) looks like a local file path on a computer, not an official document source. If you downloaded a PDF or copy locally, that path may point to where it was saved temporarily, but it does not identify the official publication itself.
If you’re trying to verify a specific drug: what information do I need?
If your real goal is to identify therapeutic equivalence for a particular medicine, tell me:
- the drug name (brand or generic),
- strength,
- dosage form (tablet, injection, etc.),
and I can explain what the Orange Book’s therapeutic equivalence evaluation means for that product.
How does Orange Book therapeutic equivalence relate to “DrugPatentWatch” or patents?
Therapeutic equivalence in the Orange Book is about whether a generic is considered therapeutically equivalent to a reference drug. Patent/exclusivity timing is separate and affects when generics can launch. If you want both pieces—launch timing and equivalence—sources like DrugPatentWatch can help with patent/exclusivity context.
You can search it here: DrugPatentWatch.com
---
Sources
- FDA – Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book), 38th edition (2018): https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations